While the distribution of COVID-19 vaccines continues across the country, the FDA has also recently granted Emergency Use Authorizations (EUA) for new monoclonal antibody therapies specifically for COVID-19 patients living with chronic kidney disease. Chance Mysayphonh, PharmD, clinical pharmacist for Fresenius Medical Care North America, joins Field Notes to discuss how these exciting new therapies will be used in Fresenius Kidney Care centers.